Skip to main content

Advertisement

SpringerLink
Log in

Optimal vancomycin doses for methicillin-resistant Staphylococcus aureus infection in urological renal dysfunction patients

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the optimal dose of vancomycin (VCM) for methicillin-resistant Staphylococcus aureus infections in the urological patients including renal dysfunction.

Methods

We had 143 sets of available data from the consecutive patients treated in the urological department for analysis in VCM dose, VCM trough and estimated glomerular filtration rate: eGFR at VCM trough examination. Patients were classified according to eGFR level, and we calculated the regression line between VCM dose and VCM trough accordingly.

Results

Median VCM dose were 1000 (range 500–3500) mg per day, the VCM trough was 15.6 ± 7.89 μg/ml, and eGFR was 61.1 ± 27.2 ml/min/1.73 m2. Our regression analysis (x axis: VCM dose (mg) and y axis: VCM trough (μg/ml) was statistically significant in the group with eGFR of 30–60 ml/min/1.73 m2 (y = 26.103x + 481.7; r 2 = 0.1291) and the group with eGFR of 60–90 ml/min/1.73 m2 (y = 48.891x + 350.75; r 2 = 0.2561) in both with (p = 0.021 and 0.035, respectively) or without (p = 0.012 and 0.004, respectively) adjustments by body weight for VCM doses.

Conclusion

These data showed that the optimal dose of VCM varied according to the eGFR value in consecutive urological patients with various renal functions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285–292

    Article  PubMed  Google Scholar 

  2. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS (2008) Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 52:37–44

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A (2012) Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 68:1243–1255

    Article  CAS  PubMed  Google Scholar 

  4. Wong-Beringer A, Joo J, Tse E, Beringer P (2011) Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 37:95–101

    Article  CAS  PubMed  Google Scholar 

  5. De Waele JJ, Danneels I, Depuydt P, Decruyenaere J, Bourgeois M, Hoste E (2013) Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. Int J Antimicrob Agents 41:434–438

    Article  PubMed  Google Scholar 

  6. Robles-Piedras AL, González-López EH (2009) Therapeutic drug monitoring of vancomycin. Proc West Pharmacol Soc 52:21–23

    PubMed  Google Scholar 

  7. Deng C, Liu T, Zhou T, Lu H, Cheng D, Zhong X, Lu W (2013) Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. Int J Clin Pharmacol Ther 51:407–415

    Article  CAS  PubMed  Google Scholar 

  8. Contreiras C, Legal M, Lau TT, Thalakada R, Shalansky S, Ensom MH (2014) Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. Can J Hosp Pharm 67:126–132

    PubMed Central  PubMed  Google Scholar 

  9. Levin A, Stevens PE (2014) Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85:49–61

    Article  PubMed  Google Scholar 

  10. Conil JM, Georges B, Breden A, Ruiz S, Cougot P, Fourcade O, Saivin S (2014) Estimation of glomerular filtration rate to adjust vancomycin dosage in critically ill patients: superiority of the Chronic Kidney Disease Epidemiology Collaboration equation? Anaesth Intensive Care 42:178–184

    CAS  PubMed  Google Scholar 

  11. Fahimi F, Emami S, Rashid Farokhi F (2012) The rate of antibiotic dosage adjustment in renal dysfunction. Iran J Pharm Res 11:157–161

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Schaumburg F, Köck R, Mellmann A et al (2012) Population dynamics among methicillin-resistant Staphylococcus aureus isolates in Germany during a 6-year period. J Clin Microbiol 50:3186–3192

    Article  PubMed Central  PubMed  Google Scholar 

  13. Shigemura K, Osawa K, Mukai A, Yoshida H, Fujisawa M, Arakawa S (2013) Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011. J Antibiot (Tokyo) 66:273–276

    Article  CAS  Google Scholar 

  14. Pottinger PS (2013) Methicillin-resistant Staphylococcus aureus infections. Med Clin North Am 97:601–609

    Article  PubMed  Google Scholar 

  15. Nichol KA, Adam HJ, Roscoe DL et al (2013) Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. J Antimicrob Chemother 68:i47–i55

    Article  CAS  PubMed  Google Scholar 

  16. Jelassi ML, Benlmouden A, Lefeuvre S, Mainardi JL, Billaud EM, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique (2011) Level of evidence for therapeutic drug monitoring of vancomycin. Therapie 66:29–37

    Article  PubMed  Google Scholar 

  17. Gould IM (2007) MRSA bacteraemia. Int J Antimicrob Agents 30:S66–S70

    Article  CAS  PubMed  Google Scholar 

  18. El Nekidy WS, El-Masri MM, Umstead GS, Dehoorne-Smith M (2012) Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study. Can J Hosp Pharm 65:436–442

    PubMed Central  PubMed  Google Scholar 

  19. Chung J, Oh JM, Cho EM, Jang HJ, Hong SB, Lim CM, Koh YS (2011) Optimal dose of vancomycin for treating methicillin-resistant Staphylococcus aureus pneumonia in critically ill patients. Anaesth Intensive Care 39:1030–1037

    CAS  PubMed  Google Scholar 

  20. Hermida J, Tutor JC (2006) Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit 28:326–331

    Article  CAS  PubMed  Google Scholar 

  21. Pea F, Porreca L, Baraldo M, Furlanut M (2000) High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 45:329–335

    Article  CAS  PubMed  Google Scholar 

  22. Moellering RC Jr, Krogstad DJ, Greenblatt DJ (1981) Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 3:S230–S235

    Article  PubMed  Google Scholar 

  23. Rybak MJ, Lomaestro BM, Rotschafer JC et al (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325–327

    Article  PubMed  Google Scholar 

  24. Rodvold KA, Blum RA, Fischer JH et al (1988) Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 32:848–852

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mr. Kazuhiro Yamamoto for data analyses.

Conflict of interest

We have no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Katsumi Shigemura, Fukashi Yamamichi, Kazushi Tanaka, Soichi Arakawa & Masato Fujisawa

  2. Infection Control and Prevention, Kobe University Hospital, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Katsumi Shigemura, Kayo Osawa, Issei Tokimatsu & Soichi Arakawa

Authors
  1. Katsumi Shigemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayo Osawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fukashi Yamamichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazushi Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Issei Tokimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Soichi Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masato Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsumi Shigemura.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shigemura, K., Osawa, K., Yamamichi, F. et al. Optimal vancomycin doses for methicillin-resistant Staphylococcus aureus infection in urological renal dysfunction patients. Int Urol Nephrol 47, 887–891 (2015). https://doi.org/10.1007/s11255-015-0973-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-015-0973-5

Keywords

Search

Navigation